Shri Kalyan Holdings is a non-banking financial company (NBFC) that primarily provides corporate and individual loans and manages a proprietary investment portfolio of equity and mutual funds.
The company lacks a durable competitive advantage, as evidenced by a 50% revenue CAGR decline and an average net margin of -137%. There is no evidence of low-cost funding or proprietary distribution that would allow for sustainable excess returns over the cost of capital.
Capital allocation is poor, characterized by a shrinking loan book and significant accumulated losses that have prevented dividend payments for years. Reinvestment in the core lending business has failed to generate returns above the cost of equity, with ROE averaging a meager 1.7%.
The company's slow-motion liquidation reached its terminal phase as the loan book continued to shrink, driven by a catastrophic -50% revenue CAGR that management failed to arrest. The persistent operational losses, which historically averaged -137% of margins, eventually exhausted the remaining equity base. Regulatory scrutiny intensified following repeated filing delays and auditor turnover, leading to a total loss of market access. The high concentration of related-party loans proved unrecoverable, and the lack of a functional CFO or internal controls left the entity a hollow shell with no viable path to profitability.
RichFakir rates Shri Kalyan Holdings Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shri Kalyan Holdings Ltd is trading about 66% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shri Kalyan Holdings Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shri Kalyan Holdings Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →